Life beyond kinases: structure-based discovery of sorafenib as nanomolar antagonist of 5-HT receptors.

Article Details

Citation

Lin X, Huang XP, Chen G, Whaley R, Peng S, Wang Y, Zhang G, Wang SX, Wang S, Roth BL, Huang N

Life beyond kinases: structure-based discovery of sorafenib as nanomolar antagonist of 5-HT receptors.

J Med Chem. 2012 Jun 28;55(12):5749-59. doi: 10.1021/jm300338m. Epub 2012 Jun 19.

PubMed ID
22694093 [ View in PubMed
]
Abstract

Of great interest in recent years has been computationally predicting the novel polypharmacology of drug molecules. Here, we applied an "induced-fit" protocol to improve the homology models of 5-HT(2A) receptor, and we assessed the quality of these models in retrospective virtual screening. Subsequently, we computationally screened the FDA approved drug molecules against the best induced-fit 5-HT(2A) models and chose six top scoring hits for experimental assays. Surprisingly, one well-known kinase inhibitor, sorafenib, has shown unexpected promiscuous 5-HTRs binding affinities, K(i) = 1959, 56, and 417 nM against 5-HT(2A), 5-HT(2B), and 5-HT(2C), respectively. Our preliminary SAR exploration supports the predicted binding mode and further suggests sorafenib to be a novel lead compound for 5HTR ligand discovery. Although it has been well-known that sorafenib produces anticancer effects through targeting multiple kinases, carefully designed experimental studies are desirable to fully understand whether its "off-target" 5-HTR binding activities contribute to its therapeutic efficacy or otherwise undesirable side effects.

DrugBank Data that Cites this Article

Binding Properties
DrugTargetPropertyMeasurementpHTemperature (°C)
Cyproheptadine5-hydroxytryptamine receptor 2AKi (nM)0.46N/AN/ADetails
SorafenibPlatelet-derived growth factor receptor betaIC 50 (nM)37N/AN/ADetails
SorafenibRAF proto-oncogene serine/threonine-protein kinaseIC 50 (nM)52N/AN/ADetails
SorafenibVascular endothelial growth factor receptor 1IC 50 (nM)31N/AN/ADetails
SorafenibVascular endothelial growth factor receptor 2IC 50 (nM)59N/AN/ADetails
SorafenibVascular endothelial growth factor receptor 3IC 50 (nM)16N/AN/ADetails